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ABSTRACT 
Changes in methylation of promoter or first exon may mimic the effect of mutations of 
various tumor suppressor genes (TSGs) or proto- oncogene. Repression of various genes 
during malignant transformation is due to CpG island hypermethylation and chromatin 
remodeling. Transcriptional-silencing is due to the Hypermethylation of promoter of 
various TSGs. However, hypomethylation of regulatory DNA sequences activates 
transcription of proto-oncogene, retrotransposons, as well as genes encoding proteins 
involved in genomic instability and malignant cell metastasis. The methylation of 
genomic DNA in malignant cells is catalyzed by DNA methyltransferases DNMT1. DNA 
methylation can be induced by the tobacco-specific carcinogen NNK. The role of 
DNMT1-mediated methylation in tobacco carcinogenesis remains unclear. In a human 
lung cell line, glycogen synthase kinase 3β (GSK3β) phosphorylatedDNMT1 to recruit β-
transducin repeat–containing protein (βTrCP), resulting in DNMT1 degradation, and that 
NNK activated AKT, inhibiting GSK3β function and thereby attenuating DNMT1 
degradation. Chemotherapy using DNA intercalators is one of the most successful 
approaches to cancer treatment. Induction of apoptosis in tumor cells is due t DNA 
intercalators that are believed to inhibit DNA polymerases and topo-isomerases, . The 
inhibition  of DNMT1 the primary DNA methyltransferase in mammalian cells 
,enzymatic activity is done by the  DNA intercalators, such as doxorubicin. Expression 
levels of DNMT1 in tumor cells may affect the effectiveness of doxorubicin in 
chemotherapy. Global hypomethylation in the absence of DNMT1down-regulation is 
apparent in non-primate placentas and invitro derived human cyto-trophoblast stem cells, 
suggesting that DNMT1down-regulation is not an absolute requirement for genomic 
hypomethylation in all instances. Here, we worked with the lymph node cancer tissue and 
found that the suppression of the activity along with other effects caused by other genes 
is responsible for the cancer development in the lymph node tissue. 
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INTRODUCTION 
Epigenetics: 
The term Epigenetics was coined by C. H. Waddington in 1942.Epigenetics can be 
defined as a change in phenotype that is heritable but does not involve DNA mutation. 
Furthermore, the change in phenotype must be switch-like, "ON" or "OFF;' rather than a 
graded response, and it must be heritable even if the initial conditions that caused the 
switch disappear.                   
 
Epigenetic code: 
The epigenetic code is hypothesized to be a defining code in every eukaryoticcell 
consisting of the specific epigenetic modification in each cell. Histone -modifications 
defined by the histone code and additional epigenetic modifications such as DNA 
methylation together constitutes the Epigenetic code. 
Histone modifications: 
 Histones are frequently subjected to covalent modifications. Various chromatin-
dependent processes including transcription are due to the histone.  The types of the 
histone modifications (fig: 1) are as follows; 
De/Acetylation, Methylation, Phosphorylation, Ubiquitination, Sumoylation 
Also, multiple modifications may occur at the same time may work together to change 
the behavior of the nucleosome. The idea that regulation of gene transcription in a 
systematic and reproducible way by multiple dynamic modifications is called the histone 
code.We know that the histone modifications mainly the Histone acetylation and 
methylation are mainly interrelated with the DNA methylation and also the chromatin 
remodeling.             . 
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Chromatin remodeling: 
Chromatin remodeling (fig. 2)is the enzyme-assisted movement of nucleosomes on DNA. 
Chromatin remodelers are multiprotein complexes that are large in size and, use the 
energy of ATP hydrolysis to mobilize and restructure nucleosomes. 146 base pairs of 
DNA can be wrapped by nucleosomes in approximately 1.7 turns around a histone-
octamer disk, and the DNA inside each nucleosome is generally inaccessible to DNA-
binding factors. Access to the underlying DNA to enable transcription, chromatin 
assembly, DNA repair, and other processes can be provided by the remodelers. Thus, 
remodelers convert the energy of ATP hydrolysis into mechanical force to mobilize the 
nucleosome.  
 
Fig 2: The chromatin remodeling in the nucleosome.(Lori et.al., (October 2007)) 
 
DNAMETHYLATION: 
The DNA of vertebrate animals is covalently modified by methylation of the cytosine 
base in the dinucleotides sequence 5'CpG3'. CpG is an abbreviation for cytosine and 
guanine separated by a phosphate, which links the two nucleotides together in DNA. 
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A) In Normal mammalian cell: 
In mammals, during embryonic development and maintained by a copying mechanism 
when cells divide DNA methylation patterns are established. Molecular and genetics 
studies have shown that DNA cytosine methylation is associated with gene silencing and 
plays an important role in developmental processes such as; 
 X-chromosome inactivation ---In each body cell (somatic cell) of the developing 
baby girl, one of the X chromosomes becomes very shortened and condensed so 
that most of its genes are not able to be ‗read‘ by the cells. An examination of 
female cells under a microscope reveals a dark body in the cell (called a Barr 
body) which is the inactivated X chromosome.  
 Genomic imprinting---   Genomic imprinting can be loosely defined as the 
gamete-of-origin dependent modification of phenotype. That is, the phenotype 
pointed in a locus is differentially modified by the sex of the parent contributing 
that particular allele.   
 
B) In Cancer cell: 
DNA methylation patterns in tumor cells are altered relative to those of normal cells 
(Feinberg et al. 2004) was recognized nearly twenty years ago. Tumor cells exhibit 
region-specific hypermethylation of the genome accompanied global hypomethylation 
by events (Baylin and Ohm, 2006).Most of the hypomethylation occurs in repetitive 
DNA that is normally hyper methylated (Yoder et al., 1997).  This result in increased 
transcription from transposable elements and an elevated mutation rate due to mitotic 
recombination.  Regions that are frequent targets of hypermethylation. Development of 
the cancer in the cells due to the DNA methylation (as shown in Fig 3). 
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DNMTs (DNA methyltransferases (DNMTs)) 
 The mammalian DNMTs family encompasses DNMT1,DNMT2, DNMT3A and 
DNMT3B. This family is classified into de novo and maintenance methyltransferases. 
 During replication, maintenance DNMT1 binds to methyl groups to the hemimethylated 
DNA whereas de novo DNMT3A and DNMT3B add methyl groups .CpG di-nucleotides 
of unmethylated DNA. Structures of the DNMTs (as shown in fig: 4) vary based on 
which their function varies from each other. 
 
Fig 4: The structures of the DNA methyltransferase family members.( Michał W. Łuczak  
et.al.,2010) 
DNA METHYLTRANSFERASE1 (DNMT 1): 
DNMT1gene encodes DNA (cytosine-5)-methyltransferase 1 is an enzyme that in 
humans. The DNMT 1 in the cell helps in the proper maintenance of the cell. 
Establishment and regulation of tissue-specific patterns of methylated cytosine residues 
are due to the  role of DNA (cytosine-5- )-methyltransferase 1. Certain human tumors and 
developmental abnormalities are due to the aberrant methylation patterns. This is the 
reason why the DNMT1 is known to be the ―Maintenance DNA methyltransferase‖. 
DNMT 1 helps in the maintenance methylation of the genes during the transcription(as 
shown in fig: 5). 
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REVIEW OF LITERATURE 
Maintenance methylation pattern by DNMT 1 
The role of DNA methylation in cancer development (Michał W. Łuczak  et.al.,2010) 
 
 DNA methylation and covalent modification of histones together constitutes the 
Epigenetic modifications .These alterations exert a significant impact on the 
regulation of gene expression. and  are  reversible  but  very  stable . 
 Methylation changes in the promoter or first exon may mimic the effect of 
mutations of various tumor suppressor genes (TSGs) or proto-oncogene. 
 Carcinogenesis is one of the results from aberrations in genomic DNA methylation 
that includes hypermethylation and hypomethylationof promoter or first exon of 
cancer-related genes.  
 Transcriptional silencing is due to the Hypermethylation of promoter of various 
TSGs . 
 However, hypomethylation of regulatory DNA sequences activates transcription of 
proto-oncogene, retro-transposons, as well as genes encoding proteins involved in 
genomic instability and malignant cell metastasis.  
 Genomic DNA in malignant cells undergoes methylation and it is catalyzed by 
DNA methyltransferases DNMT1 and DNMT3B, revealing significantly elevated 
expression indifferent types of cancers. 
  The target of therapeutic treatment in cancer is the reversibility of 
hypermethylation . 
 DNMT1and DNMT3B inhibitors including 5-Aza-2‘-deoxycytidine and antisense 
oligo-nucleotides have been applied in clinical trials of such treatment. 
 Proto-oncogene mutation results in formation of oncogene and its protein product 
exhibits sustained activity responsible for malignant transformation of cells. 
 The presence of m5CpG in genomic DNA is associated with condensation of 
chromatin, stabilization of chromosomes, transcriptional silencing of X 
chromosome, genomic imprinting and tissue-specific silencing of gene expression.  
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 Epigenetic regulation coordinates gene expression during cell differentiation in 
mammalian embryogenesis. 
 DNA methyltransferases (DNMTs) that can be divided into maintenance and de 
novo DNMTs  that catalyzes  the  methylation of mammalian genomic DNA . 
 Two types of DNMT inhibitors are now in clinical trials of cancer treatment: 
nucleoside analog 5-Aza-2‘-deoxycytidine (5-aza-CdR) which is incorporated into 
DNA and inactivates DNMTs and antisense oligo-nucleotide which induces 
degradation of DNMT1 mRNA and inhibits enzyme biosynthesis. 
 Targeted gene silencing by chimeric DNA-MTases resembles endogenous 
regulation, which often includes the piggyback transporting of DNA- MTases to 
target genes by transcription factors and other chromatin interacting proteins. 
  Different studies have demonstrated an interaction of Dnmt3a with p53 and RP58 
transcription factors, the retinoic acid receptor, EZH2 and SetDB1both histone 
methyltransferases ( Li et al. 2006; Vireet al. 2006), Karopsi‘s sarcoma-associated 
herpes virus protein LANA (Shamayet al. 2006), human papilloma virus protein E7 
(Vireet al. 2006), as well as Mbd3 and Brg1. 
 Therefore, the application of chimeric MTases for external gene regulation is one 
example of successful imitation of nature in biotechnology. Future work will show 
if targeted gene silencing by chimeric DNA MTases will hold its promises. 
Expression of DNA Methyltransferase (DNMT) 3a , 3b and 1Proteins in Human 
Hepatocellular Carcinoma: (Takanori et al., 2006) 
 Aberrant alterations of a DNA methylation is one of the most consistent epigenetic 
changes found in human cancers. (Girault et al., 2003). 
 DNA methylation patterns using the proofreading or re-methylation function 
(Hattori et al., 2004).  
 Hepato-carcinogenesis is due to the aberrant hypermethylation of CpG islands, and 
it has been reported that tumor suppressor genes in hepatocellular carcinomas 
(HCCs) are affected by such silencing (Saito et al., 2001).  
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 There were no significant associations between DNMT expression and age, sex, 
tumor size, infiltration to the capsule or underlying liver disease. 
  DNA methylation involves in the early developmental stages of HCC with a 
background of chronic liver disease, including CH and LC. 
 Stepwise progression of methylating events contributes to multistep hepato-
carcinogenesis. 
 The levels of DNMT1, DNMT3a and DNMT3b mRNA in HCCs are significantly 
higher than in noncancerous liver tissues, including normal, chronic CH and LC 
tissues (Saito et al., 2001). 
 Faint cytoplasmic expression and strong nuclear expression of DNMT3a and 
DNMT3b can be seen through the immuno-histochemical staining. 
  However, a previous report found no significant relationship between DNMT 
mRNA levels and portal vein involvement and tumor differentiation in HCCs 
(Saito et al., 2001). 
 But the same research group reported a significant relationship betweenDNMT1 
protein expression and portal vein involvement or tumor differentiation (Saito et 
al.,2003). 
  In addition, DNMTs may represent new prognostic markers and potential 
therapeutic targets in HCC. 
 In conclusion, the present study suggests that over-expression of DNMT proteins 
in HCCs may be a predictive factor for poor survival. 
 
In vivo stabilization of the Dnmt1 (cytosine-5)-methyltransferase protein: (Feng and 
J. Chaillet, 2002) 
 
 The cytoplasm of the oocyte synthesizes and stores the Dnmt1o form of the 
Dnmt1 (cytosine-5)-methyltransferase and that Dnmt1o is used after fertilization 
to maintain methylation patterns on imprinted genes. 
 Dnmt1o is replaced by the Dnmt1 form after implantation of the blastocyst, , due 
to the change in additional 118 aa is present at the amino terminus of the Dnmt1o. 
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 Mice were generated with a mutant allele, Dnmt1V which synthesized Dnmt1o 
instead of Dnmt1 in all somatic cells to investigate functional differences between 
Dnmt1o and Dnmt1.  
 Homozygous Dnmt1V mice were phenotypically normal, due to the  normal levels 
of genomic methylation, that indicates Dnmt1o adopts the maintenance methyl-
transferase function of Dnmt1. 
 In heterozygous Dnmt1V__ embryonic stem cells and early embryos, equal 
steady-state levels of Dnmt1o and Dnmt1 proteins were produced from the 
Dnmt1V and the WT Dnmt1 alleles, respectively. 
 The intrinsic stability of the Dnmt1o protein is the most likely reason for its use as 
a maternal-effect protein; stable ooplasmic stores of Dnmt1o would be available 
to traffick into the nuclei of the eight-cell stage embryo and maintain methylation 
patterns on alleles of imprinted genes during the fourth embryonic S phase. 
 Based on in vitro studies, Dnmt1 has a 5- to 30-fold preference for 
hemimethylated DNA substrates over unmethylated substrates, indicating that the 
main function of Dnmt1 is to maintain methylation patterns. 
 There are two isoforms of Dnmt1, which are expressed in a sequential pattern 
during development. 
 Growing oocyte shows the Dnmt1o is a maternal-effect protein, stored in the 
ooplasm of the mature M2 oocyte, and that functions after fertilization to maintain 
DNA methylation patterns on alleles of imprinted genes.  
 Alternative oocyte-specific Dnmt1 promoter synthesizes Dnmt1o. 
 Dnmt1o transcripts are not found in the embryo after the zygote stage due to 
which  promoter is turned off after fertilization. 
 The oocytes of females that are homozygous for a targeted deletion of the oocyte-
specific promoter lack Dnmt1o. 
  Offspring of these homozygous Dnmt1_1o females exhibit a 50% reduction in 
the number of normally methylated alleles of imprinted genes, and most of them 
die during the later stages of fetal development. 
 Role of Dnmt1o in maintaining methylation patterns can be observed at just one 
embryonic S phase.  
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 Nuclei at just one cleavage stage of pre-implantation development, namely the 
eight-cell stage traffics‘ oocytes derived Dnmt1o. 
  A functional difference between the two proteins, should there to be one to be 
mediated through this Dnmt1-specific domain.  
 Amino terminal domain of the human DNMT1 protein is known to interact with a 
transcriptional repressor protein DMAP1. 
 Gene specific interaction between the human DNMT1 and DMAP1 proteins (or 
between the mouse Dnmt1 and Dmap1 proteins) may possibly affect the 
maintenance methylation function of Dnmt1, but this is not known. 
 
The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 
accumulation and tumor suppressor gene hypermethylation in mice and lung cancer 
patients:  (Lin et.al. 2002). 
 
 Over-expression of DNA methylation process is catalysed by the DNA 
methyltransferase 1 (DNMT1) and  may lead to many human diseases, including 
cancer. 
 NNK is the tobacco-specific carcinogen that induces DNA methylation. 
 DNMT1 is reported to be especially over-expressed in lung and liver cancer patients 
that are smokers. 
 Nitrosamine 4-(methylnitro-samino)-1-(3-pyridyl)-1-butanone (also known as 
nicotine-derived nitrosamine ketone; NNK) is the key ingredient of tobacco smoke 
carcinogen that systemically induces tumors of the lung in rats, mice, and hamsters 
and also it plays a major role in lung carcinogenesis. 
 Clinical studies indicated promoter hypermethylation at more than 20 TSGs in lung 
tumors is due to smoking.  
 The molecular mechanisms of DNMT1 over-expression in relation to NNK are 
studied the using lung cancer as a model, we performed cell, animal, and clinical 
studies to analyze. 
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 DNMT1 protein accumulation is due to the phenomenon in which NNK activates 
AKT, and then inhibits GSK3β/β-transducin repeat–containing protein–mediated 
protein degradation. 
 Several significant human diseases are because of the epigenetic disorders, among 
them many of which are mediated by altered DNMT1 expression and /activity. 
 In mouse and rat studies, liver or lung tumor formation is due to the exposure to the 
tobacco-specific carcinogen NNK that induces hypermethylation of multiple TSG 
promoters. 
  In addition, their study revealed what we believe to be a new mechanism of NNK-
induced DNMT1 protein stability by AKT/hnRNP-U/βTrCP nucleo-cytoplasmic 
shuttling. 
 Furthermore, the NNK-induced DNMT1 proteins (as shown in fig: 6) bound to 
promoters of various TSGs and caused promoter hypermethylation of the bound 
TSGs, which ultimately led to tumorigenesis and poor prognosis in clinical 
manifestation. 
 
Fig :6 Proposed model to illustrate the accumulation of nuclear DNMT1 by NNK-
induced AKT/GSK3β/βTrCP/hnRNP-U signaling leading to promoter hypermethylation 
and tumor genesis. 
Doxorubicin Inhibits DNMT1, Resulting in Conditional Apoptosis :(Tomoki and 
Keith, 2004) 
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 Amsacrine, actinomycin, mitoxantrone, and doxorubicin are the DNA intercalating 
agents, such as have been employed as anticancer drugs and are in routine clinical use 
as chemotherapeutic agents. 
 DNA polymerases and topo-isomerases are inhibited by DNAintercalators, resulting in 
the induction of apoptosis in tumor cells, other factors potentially inhibited by the 
anthracycline antibiotics remain to be elucidated. 
 DNA intercalators acts as a inhibitor for the enzymatic activity of DNMT1, the primary 
DNA methyltransferase in mammalian cells can be seen, such as doxorubicin, in an  
in vitro assay. 
 One of the most typical anticancer drugs commonly employed in the clinic is nothing 
but the DNA  intercalator and it is well accepted that the antitumor activity of 
doxorubicin is caused by the formation of a cleavable complex of topoisomerase II, 
resulting in apoptosis. 
 Doxorubicin is indicated in the treatment of a broad spectrum of solid tumors (e.g., 
breast, bladder, endometrium, thyroid, lung, ovary, stomach, and sarcomas of the bone) 
and in the treatment of lymphoma, as well as acute lymphoblastic and myeloblastic 
leukemias (Carter, 1975).  
 Induction of cardiomyopathy is one of the most important and clinically relevant side 
effects of doxorubicin. 
 The primary enzyme responsible for maintenance of DNA methylation on genomic 
DNA is DNA methyltransferase 1 (DNMT1) (Bestor et al., 1988; Yoder et al., 1996). 
 Chromosome instability and dysregulation of transcription are caused by the disruption 
of DNMT1 function causes, and ultimately leads to apoptotic cell death (Ehrlich, 2002). 
 Deletion of the Dnmt1 gene is due to Cre-mediation resulted in demethylation of 
genomic DNA in cultured murine fibroblasts and led to p53-dependent cell death 
suggesting that loss of DNMT1 induces apoptosis. 
 However, other studies have shown that deletion of the DNMT1 gene is compatible with 
cell viability in the HCT116 cell line. 
 DNMT1 did not induce apoptosis in this cell line.  
 Apoptosis mediated by doxorubicin is of great interest to determine whether DNMT1 is 
associated with it . 
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 From the enzymatic studies it is clear that doxorubicin is a potent inhibitor of DNMT1 
activity via DNA intercalation.  
 It was also examined that doxorubicin-induced cytotoxicity using the HCT116 human 
colorectal cancer cell line as a model system. 
 There is no conditional apoptosis in cells that lacks the major DNA methyltransferase 
DNMT1. 
 However, DNMT1_/_ HCT116 cells can be made apoptosis inducible by reintroduction 
of DNMT1. 
 These results suggests that interaction of DNMT1 and doxorubicin may contribute to 
the induction of apoptosis in cancer cells. and that DNMT1 is one of the important 
targets for doxorubicin . 
 
DNA Methyltransferase 1 (DNMT1) gene activity in human lymphomas correlates 
with aberrant p53geneexpression :( Qayum and Ashraf, 2002). 
 
  The DNA Methyltransferase 1 (DNMT1) gene is the gene that acts as a mutagen for 
tumor suppressor genes by causing hypermethylation and subsequent TA mutations of 
CpG islands located in the promoter regions of these genes. 
  Increased DNMT1 gene activity leads to the increased aberrant p53 gene expression 
in human lymphomas. 
  Generally, it is agreed that DNA methyltransferase activity increases due to the 
global hypomethylation in malignant cells accompanied by regional hyper-
methylation and in most cases also an increase of the methylation enzyme.  
  The group of haematological malignancies is no exception to abnormal methylation 
patterns. 
  Silencing of p53 and its homologous p73 (tumor suppressor) gene expression is due 
to the hypermethylation which results in acute lymphoblastic leukaemia, Burkitt‘s 
lymphoma, non-Hodgkin‘s lymphoma, acute myelogenous leukaemia and multiple 
myeloma. 
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  It has been established that 5-Methylcytosine (5MeC) acts as a ‗hot spot‘ for further 
mutations, so that it is changed to Thymine by spontaneous deamination and the 
subsequent addition of a keto group. 
 It was found that 28% of mutations at the human p53 gene locus were due to C to T 
transitions at Cytosine-Guanine pair (CpG) dinucleotides that are located at the 
promoter regions of these tumor suppressor genes. 
 We can observe significant increase the in expressions of the DNMT1 gene and the 
aberrant p53 gene in the lymphoma lymph node cells. 
 Overall increase in the mRNA expression in lymphoma cells can result in increased 
expressions of the DNMT1 and p53 genes in lymphoma cells that merely reflects an 
by significantly increased PolydT expression. 
 Increased DNMT1 activity has been related to DNA hypomethylation and indeed 
carcinogenesis, a fact that is explained by decreased levels of the methyl donor S-
Methyl Adenosine (SAM) in some tumor cell types; the presumed pathway is 
increased hypomethylation of promoter regions of tumor promoter genes in excess of 
the presumed hypomethylation of tumor suppressor genes, paradoxically. 
 It appears then that DNMT1 controls methylation in both suppressor and promoter 
genes and other circumstances may well be determining factors for or against 
carcinogenesis, at least in some tumor types. 
 
DNA Methylation-mediated Down-regulation of DNA-Methyltransferase-1 
(DNMT1) Is Coincident with, but Not Essential for, Global Hypomethylation in 
Human Placenta: (Boris et .al., 2009) 
 
 Epigenetic down-regulation of DNMT genes mediates promoter methylation as a 
potential regulator of global methylation levels in placental tissue. 
 Monoallelic methylation of DNMT1 has been revealed by the DNA sequencing, with 
no evidence of imprinting (parent of origin effect).  
 In vitro reporter experiments confirmed that transcriptional activity in trophoblast 
cells has been attenuated by DNMT1 promoter methylation. 
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 In non-primate placentas and invitro derived human cyto-trophoblast stem cells the 
global hypomethylation is absent leading to DNMT1 down-regulation is apparent, 
suggesting thatDNMT1 down-regulation is not an absolute requirement for genomic 
hypomethylation in all instances. 
 Gene transcription has been attenuated by DNMT1 Promoter Methylation directly . 
 No evidence was found for a direct association of DNMT1 methylation with overall 
gene expression level, with widely variable expression in different populations of 
cells (e.g. cyto-trophoblasts and CVS tissues), even where similar overall levels of 
promoter methylation were apparent. 
 However, under controlled conditions in culture, we observed both a clear negative 
correlation of DNMT1 promoter methylation with gene expression level in CVS-
derived tissue and a correlation between expression and proliferation in a model of 
trophoblast differentiation. 
  Methylation of the DNMT1 promoter may be associated with a switch to other 
regulatory elements in this tissue. 
 Growth retardation occurs specifically due to the inhibition of DNMT1 activity in 
prostate cancer-derived PC3 cells that enhances invasiveness and migratory capacity. 
 Majority of CpG island-containing genes remain unmethylated throughout 
development. 
 
Dnmt1 deficiency leads to enhanced microsatellite instability in mouse embryonic 
stem cells: 
 DNA hypomethylation is frequently seen in cancer that leads to the genomic 
instability in mouse models and some tissue culture systems. 
 Model systems to analyze the effects of DNA methyltransferase 1 (Dnmt1) deficiency 
on DNA mismatch repair (MMR) in mouse embryonic stem (ES) cells. 
 Changes in mutation rates with conflicting results are due to the disruption of Dnmt1 
(DNA methyltransferase 1)in mouse ES (embryonic stem) cells. 
 Chromosomal instability such as chromosomal loss, rearrangement, and duplication at 
endogenous loci are induced due to the hypomethylation. 
Role of DNMT 1 in cancer Page 16 
 
 Suppression of the gene loss and gene mutation of exogenously introduced trans-
genes is due to the Dnmt1 deficiency and the accompanying genomic DNA 
hypomethylation. 
 The proteins encoded by MMR genes recognize mismatched nucleotides that arise 
during DNA replication, homologous recombination, or other forms of DNA damage. 
 Impaired MMR can give rise to malignancies exhibiting microsatellite instability 
(MSI), which manifests itself as alterations in the length of simple, repetitive DNA 
sequences. 
 Both DNMT1 and MLH1 have a binding site for PCNA (Proliferating cell nuclear 
antigen), a processivity factor that is involved in DNA replication. 
 Dam methylation plays an important role in MMR strand discrimination in 
Escherichia coli and is mediated by MutH. 
 However, CpG methylation is not thought to be the strand discrimination signal in 
mammalian cells, but utilization of strand discontinuities such as nicks may be the 
signal for MMR. 
 Remarkably, using different approaches and initial goals, both studies arrived at the 
same conclusion: Dnmt1 deficiency leads to reduced MMR efficiency. 
 In the present study, we measured the slippage rate at a mononucleotide repeat tract in 
Dnmt1-deficient ES cells.  
 In addition, we extended the findings by investigating potential mechanisms of 
enhanced slippage in Dnmt1-deficient ES cells. 
 We used mouse ES cells as a model system to study whether Dnmt1 affects MMR 
efficiency. Our results demonstrated that disrupting both copies of Dnmt1 caused an 
elevated MSI. 
 Dnmt1 was identified as a novel MMR gene in a genetic screen for MMR mutants in 
Bloom‘s syndrome protein (Blm)-deficient ES cells.  
 Histone H3 acetylation increased in DNMT1-deficient human cancer cells. 
 
 Although we found that Dnmt1 loss led to MSI in mouse Excels, it is unlikely that 
this is a major mechanism by which‘s is induced in human cancers. Mutation of 
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DNMT1 has not been demonstrated to be common in human cancers .Moreover; loss 
of Dnmt1 is lethal during embryonic development as well as in differentiated cells. 
 In conclusion, our study extends the current understanding of the relationship between 
DNA methylation and genomic stability to MMR. Our results suggest that Dnmt1 
may be closely linked to MMR to maintain genomic integrity. 
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OBJECTIVE 
 
To clarify the role of the DNMT1 in the aberrant hypermethylation and the regional 
hypomethylation of the TSGs in various human cancers. The main aim is to observe the 
expression levels of the DNMT 1 gene in the cancer tissues and those results were further 
compared with the normal cell. The p53 gene has been focused in among the TSGs and it 
is because this gene is involved in many cellular pathways that help in the regulation. 
Here, the expression of the DNMT1 enzyme has been examined as already discussed that 
it is having a major role in the maintenance of the genomic methylation and also the 
transcriptional regulatory changes in the human cancer. 
Our main objective was ―Analysis of the DNA Methyltransferase 1 expression and its 
possible role in various Human Cancer‖. 
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MATERIALS AND METHODS 
The Human blood was collected from CWS Hospital, Rourkela as normal human tissue 
and Gall bladder and Lymph node cancer tissues were collected from Calcutta Medical 
College, Kolkata. 
Total RNA isolation 
 Reagents and Buffers:- 
 TRIzol Reagents (Sigma), 
 Choloroform, 
 Isopropanol, 
 Ethanol (70%), 
 Denaturation Buffer 
 50 % deionized formamide, 
 2.2 M formaldehyde, 
 MOPS buffer (pH 7.0), 
 6.6 % glycerol, 
 0.5 % bromophenol,  
 Ethidium Bromide (EtBr), 
 Agarose 
 Protocol:- 
 50-100 mg of tissue in a 2 ml tube with 1 ml TRIzol was transferred. 
 Homogenized for 60 sec in the polytron. 
 200 l chloroform was added. 
 It was mixed by inverting the tube for 15 sec. 
 Incubated for 3 min at room temperature. 
 Centrifuged at 12.000 g for 15 min. 
 The aqueous phase was transferred into a fresh Eppendorf tube. 
 500 l isopropanol was added. 
 Centrifuged at max. 12.000 g for 10 min in the cold room. 
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 The pellet was washed with 500 l 70 % ethanol. 
 Centrifuged at max. 7.500 g for 5 min in the cold room. 
 The pellet was dried on air for 10 min. 
 Then the pellet was dissolved in 50-100 l DEPC-H2O. 
 Incubated for 10 min at 60 C. 
 Spectrophotometric reading was taken. 
 Analysed the RNA on a MOPS gel: 
 1-3 g RNA was dissolved in 11 l denaturation buffer. 
 1 l Ethidium bromide (1mg/ml) was added and denatured at 65 C for 15 min 
 1 % agarose gel was loaded in MOPS buffer plus 5 % formaldehyde. 
 The gel was run at 40 V for 4 h. 
 
 b)  cDNA synthesis (rt-PCR):  
Regents and Buffer:- 
 5X First Strand Buffer 
 10mM dNTP Set 
 0.1M DTT 
 Random Primers 
 RNase OUT Ribonuclease Inhibitor 
 Super Script II RNAase H- Reverse Transcriptase 
Protocol:- 
 8µl of total RNA were taken. 
 Then 3 μl Random Primers was added. 
 1 μl dNTP mix was added. 
 Then vortex and spin downed tube. 
 Incubated at 65°C for 5 min. 
 Placed tube on ice. 
 4 μl 5X Buffer, 2 μl DTT and 1μl RNAaseOut were added. 
 Then vortex and spin downed tube. 
Role of DNMT 1 in cancer Page 21 
 
 Incubated at 42°C for 1 min. 
 1μl SuperScript II RNAase H- Reverse Transcriptase was added. 
 Incubated at 42°C for 60 min. 
 Incubated at 70°C for 15 min. 
 180 μl of molecular grade water was added. 
 Nano drop 1000 was used to measure concentration. Set sample typesetting to 
Other Sample and the constant to 33. 
 Stored at -80°C. 
c) Gene specific PCR: 
Used Primers:- 
Table: 1: primers used for the experiment 
Gene Forward Primer Reverse Primer 
Tm 
DNMT 1 5‘-ACCAAGCAAGAAGTGAAGCC -3‘  
 
5‘- GCTTCCTGCAGAAGAACCTG -3‘ 
 
63.3 & 64.0 
β-Actin 5‘ - TCTACAATGAGCTGCGTGTG- 3‘ 5‘- ATCTCCTTCTGCATCCTGTC -3‘ 62.7 & 60.8 
(Patra et.al.-2002) 
d)  PCR mixture: -(Total 25µl) 
 0.2 µM dNTP- 0.5µl 
 1.5 mM MgCl2- 1.5µl 
 1x PCR Buffer- 2.5µl 
 TaqPolymerase (5U/µl)- 0.5µl 
  Primers (0.2µM)- 0.5µl & 0.5µl 
 cDNA- 2µl 
 MQ Water- 17µl 
e) PCR conditions:-  
94
o
C1:00[94
o
 C0:20; 58˚C0:20; 72
o
C 0.30]30; 72
o
C 5:00   for DNMT1. 
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RESULTS 
From Normal Tissue (Blood): 
Product Conc
n
.(µg/ml) Purity 
260/280 260/230 
Total RNA 570.32 1.34 0.82 
Table.2: Spectrophotometer results of total RNA from blood tissue 
              1  2   3    4 
                                                                                           
[Total RNA in 1% agarose gel]                                 [Total RNA in denaturation gel]  
 
Gene Conc
n
.(µg/ml) Purity 
260/280 260/230 
DNMT1 168.23 1.71 1.03 
Β-Actin 392.47 1.82 0.98 
Table.3: Spectrophotometer results of gene specific amplification product from blood 
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                                          Lane 1: DNMT1 
                                          Lane 2: DNMT3A 
                                          Lane.3: DNMT3B 
                    Lane .4: β-Actin 
 
 
 
       
From Cancerous Tissue: 
Tissue Conc
n
.(µg/ml) Purity 
260/280 260/230 
Gall Bladder Cancer 234.67 1.03 0.65 
Lymph Node Cancer 478.51 1.61 1.02 
Table.4: Spectrophotometer results of total RNA from cancerous tissue 
 
 
  1            2              3           4               
[Gene specific PCR amplification] 
Role of DNMT 1 in cancer Page 24 
 
                                                                                                                          1       2 
 
                                                         Lane.1: Lymph Node Cancer  
                                                        Lane.2: Gall Bladder Cancer 
 
 
 
 
Gene Conc
n
.(µg/ml) Purity 
260/280 260/230 
DNMT1 263.25 1.74 1.28 
β-Actin 395.35 1.73 1.19 
 
Table.5: Spectrophotometer results of gene specific amplification product from lymph 
node cancer tissue  
 
 
 
 
 
[Total RNA in denaturation gel] 
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1     2     3      4       5      6    7  8         9         10      11 
 
 
 
 
 
 
 
 
 
Fig: 6: Comparative Graph of Expression of DNMT1in both Normal & Cancer Tissue 
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DISCUSSION 
After isolation the total RNA from normal blood and Cancerous tissue, we checked their 
concentration by taking its OD in spectrophotometer, in case of Gall Bladder the 
concentration was found to be very low i.e. 234.67µg/ml, which was very low compare to 
the other samples reading. Because it was took a lot of time to processing after collecting 
the sample and also cDNA was not synthesize from the total RNA by reverse 
transcriptase PCR method due to some unsuitable condition. 
The concentration of the DNMT1 in the normal tissue is 263.25 µg/ml, and in the lymph 
node cancer tissue it is 168.23µg/ml. As shown in our investigation the concentration of 
the enzyme has been increased in the cancer tissue. So we could hypothesize that 
DNMT1 is responsible of causing the cancer. 
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CONCLUSION 
As indicated by the above result DNMT 1 expression is suppressed in Lymph Node 
cancer tissue.  So from this we can hypothesize that these suppression of DNMT1 activity 
in the cancer tissue leads to hyper-methylation of TSG i.e. p53, which in turn diminish 
the expression of p53 and causing the cancer. 
Though, we were not concluded from the above studies that, DNMT 1 is causing the 
methylation mediated pattern on promoter region of TSGs which cause gene silencing 
and cancer. But our studies relatively hypothesized the above statements.  
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